264 related articles for article (PubMed ID: 7527116)
1. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
Stenman UH; Hakama M; Knekt P; Aromaa A; Teppo L; Leinonen J
Lancet; 1994 Dec; 344(8937):1594-8. PubMed ID: 7527116
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
[TBL] [Abstract][Full Text] [Related]
3. Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland.
Auvinen A; Tammela T; Stenman UH; Uusi-Erkkilä I; Leinonen J; Schröder FH; Hakama M
Br J Cancer; 1996 Aug; 74(4):568-72. PubMed ID: 8761371
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.
Christensson A; Björk T; Nilsson O; Dahlén U; Matikainen MT; Cockett AT; Abrahamsson PA; Lilja H
J Urol; 1993 Jul; 150(1):100-5. PubMed ID: 7685416
[TBL] [Abstract][Full Text] [Related]
5. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial.
Auvinen A; Määttänen L; Finne P; Stenman UH; Aro J; Juusela H; Rannikko S; Tammela TL; Hakama M
Int J Cancer; 2004 Oct; 111(6):940-3. PubMed ID: 15300807
[TBL] [Abstract][Full Text] [Related]
6. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L.
Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF
Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381
[TBL] [Abstract][Full Text] [Related]
7. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
8. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
[TBL] [Abstract][Full Text] [Related]
9. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases.
Kuriyama M; Abrahamsson PA; Imai K; Akimoto S; Deguchi N; Shichiri Y; Sugiyama Y; Niwa T; Inoue T
Scand J Urol Nephrol; 2001 Feb; 35(1):5-10. PubMed ID: 11291689
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
11. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
12. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
13. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
[TBL] [Abstract][Full Text] [Related]
14. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
16. Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland.
Hakama M; Stenman UH; Aromaa A; Leinonen J; Hakulinen T; Knekt P
J Urol; 2001 Dec; 166(6):2189-91; discussion 2191-2. PubMed ID: 11696733
[TBL] [Abstract][Full Text] [Related]
17. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
[TBL] [Abstract][Full Text] [Related]
18. European randomized study of prostate cancer screening: first-year results of the Finnish trial.
Määttänen L; Auvinen A; Stenman UH; Rannikko S; Tammela T; Aro J; Juusela H; Hakama M
Br J Cancer; 1999 Mar; 79(7-8):1210-4. PubMed ID: 10098761
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease.
España F; Martínez M; Sánchez-Cuenca J; Vera CD; Estellés A; Jiménez-Cruz JF
Eur Urol; 1996; 30(4):512-8. PubMed ID: 8977078
[TBL] [Abstract][Full Text] [Related]
20. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
Stenman UH; Leinonen J; Alfthan H; Rannikko S; Tuhkanen K; Alfthan O
Cancer Res; 1991 Jan; 51(1):222-6. PubMed ID: 1703033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
